Two International Biopharmaceutical Organizations Sign Agreements with eResearchTechnology Totaling More Than $1.7 Million for Thorough Phase 1 ECG Studies
PHILADELPHIA, Feb. 20 /PRNewswire-FirstCall/ — eResearchTechnology, Inc. (eRT), (Nasdaq: ERES – News), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received agreements for more than $1.7 million in cardiac safety monitoring and services from two international biopharmaceutical organizations for two drug candidates in clinical development.
The agreements cover an extensive Phase I study for each compound. eRT is providing comprehensive support including the provision, training and ongoing assistance required for effective use of digital 12-lead Holter equipment designed to facilitate 24-hour digital recording of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. Each study is targeted for completion over a 90-day period.
“We are pleased to have been awarded these important studies, which illustrate the continued adoption of emerging FDA guidelines and international standards that designate the Thorough Phase I ECG Study as the definitive approach to determining the cardiac effects of new therapies on healthy volunteers,” said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. “eRT’s ability to expand capacity and throughput on a worldwide basis to perform the services associated with these demanding initiatives has proven critical in enhancing our value proposition to the global drug development community.”
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company’s financial results can be found in the company’s Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission.
SOURCE: eResearchTechnology, Inc.
